Reviews medical records of people with neuroendocrine carcinomas in Latin America
Studies how neuroendocrine carcinomas are treated and how patients do over time.
Plain-language title generated from the registry record
Registry title: Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Key facts
- Where
- Buenos Aires, ArgentinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed between August 2014 and August 2024 with a neuroendocrine carcinoma, outside or inside the lung. It is a records-only study; care stays as usual.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Neuroendocrine carcinoma outside the lung (EP-NEC), large-cell neuroendocrine carcinoma (LCNEC) or mixed, or small cell lung cancer (SCLC) or mixed. Diagnosed between August 2014 and August 2024.
- Biomarker or test result
- A tumor block collected from 2014 onwards
Main reasons for not taking part
- Another active cancer when the neuroendocrine carcinoma was diagnosed, except non-invasive skin basal cell or squamous cell cancer, or in situ cervical cancer
- Medical records that are not adequate or not accessible
- Unwilling or unable to give informed consent, if the ethics committee requires it
Read by machine on 9 November 2026.
Where in Argentina
- Hospital Britanico de Buenos AiresBuenos Aires, ArgentinaContact: Ernesto Korbenfeld (principal investigator)Taking people
- Hospital de Gastroenterología Carlos Bonorino UdaondoBuenos Aires, ArgentinaContact: Andrea Elizabeth Acosta (principal investigator)Taking people
- Instituto Alexander FlemingBuenos Aires, ArgentinaContact: Claudio Marcelo Martin (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Latin American Cooperative Oncology Group
- Trial code
- NCT07192991
- Record updated
- 8 September 2026
- Original description
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.Read full original descriptionShow less
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Inclusion: ≥18 years old; Diagnosed between August 2014 and August 2024 with one of the following:; Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Large-cell neuroendocrine carcinoma (LCNEC) or mixed; Small Cell Lung Cancer (SCLC) or mixed; Adequate and accessible medical records for data collection; Tumor block collected from 2014 onwards.
Exclusion: Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer; Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).